Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 5/20 | 0.69 |
| ▸ | NPC1 | O15118 | 5/20 | 0.69 |
| ▸ | RAB9A | P51151 | 5/20 | 0.69 |
| ▸ | KMT2A | Q03164 | 5/20 | 0.69 |
| ▸ | SMN1; SMN2 | Q16637 | 5/20 | 0.69 |
| ▸ | MAPT | P10636 | 4/20 | 0.69 |
| ▸ | PIK3CG | P48736 | 11/20 | 0.67 |
| ▸ | PIK3CA | P42336 | 9/20 | 0.64 |
| ▸ | NFKB1 | P19838 | 2/20 | 0.59 |
| ▸ | NFKB2 | Q00653 | 2/20 | 0.59 |
| ▸ | RELA | Q04206 | 2/20 | 0.59 |
| ▸ | PDE10A | Q9Y233 | 1/20 | 0.59 |
| ▸ | POLB | P06746 | 1/20 | 0.58 |
| ▸ | PIK3CD | O00329 | 2/20 | 0.57 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.55 |
| ▸ | GAA | P10253 | 1/20 | 0.55 |
| ▸ | HTT | P42858 | 1/20 | 0.55 |
| ▸ | AKT1 | P31749 | 1/20 | 0.55 |
| ▸ | MTOR | P42345 | 1/20 | 0.55 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10081045 | 0.93 | PIK3CG (0.65) | MEN1NPC1RAB9AKMT2ASMN1; SMN2 | |
| SCHEMBL10081024 | 0.92 | PIK3CG (0.61) | MEN1NPC1RAB9AKMT2ASMN1; SMN2 | |
| SCHEMBL10081070 | 0.92 | PIK3CG (0.64) | MEN1NPC1RAB9AKMT2ASMN1; SMN2 | |
| SCHEMBL10081025 | 0.92 | PIK3CG (0.64) | MEN1NPC1RAB9AKMT2ASMN1; SMN2 | |
| SCHEMBL10081071 | 0.92 | PIK3CG (0.67) | MEN1NPC1RAB9AKMT2ASMN1; SMN2 | |
| SCHEMBL10081021 | 0.92 | NPC1 (0.68) | MEN1NPC1RAB9AKMT2ASMN1; SMN2 | |
| SCHEMBL10081068 | 0.92 | PIK3CG (0.63) | MEN1NPC1RAB9AKMT2ASMN1; SMN2 | |
| SCHEMBL10081033 | 0.91 | PIK3CG (0.67) | MEN1NPC1RAB9AKMT2ASMN1; SMN2 | |
| SCHEMBL10081042 | 0.90 | PIK3CG (0.64) | MEN1NPC1RAB9AKMT2ASMN1; SMN2 | |
| SCHEMBL10081023 | 0.90 | PIK3CG (0.61) | MEN1NPC1RAB9AKMT2ASMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8268999-B2 | Tri-cyclic pyrazolopyridine kinase inhibitors | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2012-09-18 | — | — | US | disclosed |
| US-8268999-B2 | Tri-cyclic pyrazolopyridine kinase inhibitors | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2012-09-18 | — | — | US | disclosed |
| US-20120053187-A1 | TRI-CYCLIC PYRAZOLOPYRIDINE KINASE INHIBITORS | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2012-03-01 | — | — | US | disclosed |
| US-20120053187-A1 | TRI-CYCLIC PYRAZOLOPYRIDINE KINASE INHIBITORS | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2012-03-01 | — | — | US | disclosed |
| WO-2010135014-A1 | TRI-CYCLIC PYRAZOLOPYRIDINE KINASE INHIBITORS | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2010-11-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120053187-A1 | TRI-CYCLIC PYRAZOLOPYRIDINE KINASE INHIBITORS | PIK3CA, PIK3CD, PIK3CG | MEN1 3841/4885NPC1 1406/4885RAB9A 1134/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.